Добірка наукової літератури з теми "Eticlopride"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Eticlopride".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Eticlopride"
Feng, Xin, Victor M. Henriquez, Judith R. Walters, and Christy L. Ludlow. "Effects of Dopamine D1 and D2 Receptor Antagonists on Laryngeal Neurophysiology in the Rat." Journal of Neurophysiology 102, no. 2 (August 2009): 1193–205. http://dx.doi.org/10.1152/jn.00121.2009.
Повний текст джерелаMilanés, M. V., M. T. Marín, and M. L. Laorden. "Effects of morphine withdrawal on catecholaminergic neurons on heart right ventricle; implication of dopamine receptors." Canadian Journal of Physiology and Pharmacology 79, no. 10 (October 1, 2001): 885–91. http://dx.doi.org/10.1139/y01-067.
Повний текст джерелаMasuda, Masao, Setsuko Kanai, and Kyoko Miyasaka. "Inhibitory effect of central dopamine on basal pancreatic secretion in conscious rats." American Journal of Physiology-Gastrointestinal and Liver Physiology 274, no. 1 (January 1, 1998): G29—G34. http://dx.doi.org/10.1152/ajpgi.1998.274.1.g29.
Повний текст джерелаGiuliani, Daniela, and Francesca Ferrari. "Involvement of Dopamine Receptors in the Antipsychotic Profile of (−) Eticlopride." Physiology & Behavior 61, no. 4 (April 1997): 563–67. http://dx.doi.org/10.1016/s0031-9384(96)00503-3.
Повний текст джерелаWang, Yu, Krisztina Harsanyi, and Stuart C. Mangel. "Endogenous Activation of Dopamine D2 Receptors Regulates Dopamine Release in the Fish Retina." Journal of Neurophysiology 78, no. 1 (July 1, 1997): 439–49. http://dx.doi.org/10.1152/jn.1997.78.1.439.
Повний текст джерелаLi, Wei, William M. Doyon, and John A. Dani. "Quantitative unit classification of ventral tegmental area neurons in vivo." Journal of Neurophysiology 107, no. 10 (May 15, 2012): 2808–20. http://dx.doi.org/10.1152/jn.00575.2011.
Повний текст джерелаBernstein, Seth N., and Richard J. Beninger. "Turning in Rats Following Intraaccumbens Shell Injections of Amphetamine or Eticlopride." Pharmacology Biochemistry and Behavior 65, no. 2 (February 2000): 203–7. http://dx.doi.org/10.1016/s0091-3057(99)00194-x.
Повний текст джерелаDong, Zhanglei, Bingwu Huang, Chenchen Jiang, Jiangfan Chen, Han Lin, Qingquan Lian, and Binbin Wu. "The Adenosine A2A Receptor Activation in Nucleus Accumbens Suppress Cue-Induced Reinstatement of Propofol Self-administration in Rats." Neurochemical Research 46, no. 5 (February 22, 2021): 1081–91. http://dx.doi.org/10.1007/s11064-021-03238-9.
Повний текст джерелаWATANABE, Kiyoko, Toshimitsu FUKUMURA, Shigeaki SASAKI, Minoru MAEDA, and Shuzo TAKEHARA. "New Fluorine-Substituted Analogue of Eticlopride with High Affinity toward Dopamine D2 Receptors." CHEMICAL & PHARMACEUTICAL BULLETIN 39, no. 12 (1991): 3211–14. http://dx.doi.org/10.1248/cpb.39.3211.
Повний текст джерелаKmieciak-Kołada, K., J. Pawłowski, E. Obuchowicz, and Z. S. Herman. "Eticlopride modifies the food intake by its influence on neuropeptide Y in the hypothalamus." Pharmacological Research 31 (January 1995): 105. http://dx.doi.org/10.1016/1043-6618(95)86681-7.
Повний текст джерелаДисертації з теми "Eticlopride"
Thompson, K. N., Ivy A. Click, R. A. Best, S. K. Thacker, and Russell W. Brown. "Acute Eticlopride Treatment Alleviates Cognitive Deficits Produced by Neonatal Quinpirole Treatment." Digital Commons @ East Tennessee State University, 2004. https://dc.etsu.edu/etsu-works/6408.
Повний текст джерелаBrown, Russell W., Kimberly N. Thompson, Ivy A. Click, Razaria A. C. Best, Stephanie K. Thacker, and Marla K. Perna. "The Effects of Eticlopride on Morris Water Task Performance in Male and Female Rats Neonatally Treated with Quinpirole." Digital Commons @ East Tennessee State University, 2005. https://dc.etsu.edu/etsu-works/6354.
Повний текст джерелаZanatta, Geancarlo. "Análise da ligação dos antipsicóticos eticloprida, haloperidol e risperidona no receptor dopaminérgico D3 : uma abordagem por ancoramento molecular, bioquímica quântica e dinâmica molecular." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/103956.
Повний текст джерелаThe introduction of antipsychotics in the clinic significantly improved the treatment of mental diseases. Nevertheless, besides the therapeutic success of the first antipsychotics (known as typical agents), their administration was associated with serious side-effects known as extrapiramidal symptoms (EPS), that compromised the treatment. The EPS include dystonic reactions, akathisia, pseudoparkinsonism and tardive dyskinesia. Following the synthesis of clozapine, a new generation of antipsychotics (known as atypical agents) with reduced EPS incidence began to appear. A set of evidences lead to the dopaminergic hypothesis of schizophrenia and many studies associated the mechanism of action of antipsychotics with the blockade of D2-like receptors. It was demonstrated that while atypical antipsychotics elicit clinical effects through 65-80% of dopamine receptor occupancy, typical agents show occupancy levels above 80%, triggering EPS. To explain the differences between typical and atypical agents, it was proposed that the former have higher affinity for the receptors, blocking them for a longer period, while atypical agents show lower affinity and are easily dissociated from the receptor, allowing the restablishment of the dopamine signaling in the nigrostriatal pathway. Recently, the blockade of D3 receptors has been discovered as an important strategy for the treatment of schizophrenia and other neurological diseases. In this study, we took advantage from the published crystallographic data of D3R complexed with eticlopride, to investigate the binding profile of the antipsychotics eticlopride, haloperidol and risperidone, through classical and quantum computational methods. Eticlopride is a potent and selective D2/D3 antagonist agent and is widely used in pharmacological research. Moreover, up to date, it is the only antipsychotic co-crystallized with a dopamine receptor. Our results highlight the central role of the residue Asp110, followed by Val82, Val107, Cys114, Ser182, Ile183, Val189, Trp342, Phe345, Phe346 and Tyr373, among others, and demonstrated for the first time the participation of Val107, Ser182, Phe188, Val82 e Asn185 in this binding. Haloperidol is a typical agent with high affinity for D2-like receptors. Although associated with the onset of EPS, haloperidol is still widely used in clinic due to its clinical properties and lower cost. In this way, the understanding of the mechanism involving dopamine receptor blockade by haloperidol is of great importance for the development of derivatives/novel agents with reduced EPS incidence. Our results unveil the conformation of haloperidol during its interaction with the D3 receptor and highlight the role of residues Asp110, Cys114, Ile183, Phe345, Phe346, Tyr365 and Tyr373. Risperidone is an atypical antipsychotics used in the treatment of schizophrenia and symptoms of irritability associated with autism spectrum disorder (ASD) in children. Our results show that risperidone binds to D3 receptor in two possible orientations, RO1 and RO2. The analyses of the individual amino acid contribution and the molecular dynamics simulations indicated that RO2 exhibits a trend to dissociate faster from the receptor than RO1, suggesting the existence of a mixing binding profile, with a fast-off behavior observed in only a fraction of ligands corresponding to orientation RO2. Our results give support to the understanding of the binding mechanisms of the important antipsychotics eticlopride, haloperidol and risperidone in the human dopamine receptor D3. Also, our results highlight the relevance of the use of classical and quantum approaches in the modeling and analysis of the individual energy contribution of every amino acid residue in the binding site of the D3 dopamine receptor.
Частини книг з теми "Eticlopride"
Hall, H., C. Köhler, and L. Gawell. "Eticlopride, a Potent Substituted Benzamide Compound Useful for the Labelling of Rat Central Dopamine-D2 Receptors in vitro and in vivo." In Dopaminergic Systems and their Regulation, 379–80. London: Palgrave Macmillan UK, 1986. http://dx.doi.org/10.1007/978-1-349-07431-0_29.
Повний текст джерелаEnna, S. J., and David B. Bylund. "Eticlopride." In xPharm: The Comprehensive Pharmacology Reference, 1–2. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.63324-0.
Повний текст джерела